Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MeiraGTx HoldingsFRA:328 -1.72%60 Equity-to-Asset is 0.54 as of Jun. 2026, which is 2% above its 10-year median of 0.53. GuruFocus rates FRA:328 with a GF Score™ of 60/100 and a GF Value™ of €70.41 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,414 Biotechnology companies, MeiraGTx Holdings ranks worse than 63.37% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MeiraGTx Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €187.1 Mil. MeiraGTx Holdings's Total Assets for the quarter that ended in Jun. 2026 was €344.1 Mil.
Therefore, MeiraGTx Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.54.
The historical rank and industry rank for MeiraGTx Holdings's Equity-to-Asset or its related term are showing as below:
FRA:328'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83 Med: 0.53 Max: 0.92
Current: 0.54
During the past 10 years, the highest Equity to Asset Ratio of MeiraGTx Holdings was 0.92. The lowest was -1.83. And the median was 0.53.
FRA:328's Equity-to-Asset is ranked worse than 63.37% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:328: 0.54
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MeiraGTx Holdings Equity-to-Asset Related Terms
MeiraGTx Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:328 vs JBIO, VOR, OMER: Equity-to-Asset Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
MeiraGTx Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (FRA:328) has a Equity-to-Asset of 0.54 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MeiraGTx Holdings and its competitors. This is near median its historical median of 0.53. According to the industry distribution chart, MeiraGTx Holdings ranks #896 out of 1414 companies in the Biotechnology industry, placing it in the top 63.4%.
Is MeiraGTx Holdings' Equity-to-Asset too high?
MeiraGTx Holdings' current Equity-to-Asset of 0.54 is near median its 10-year median of 0.53. The Biotechnology industry median Equity-to-Asset is 0.68. MeiraGTx Holdings' value of 0.54 is 20.6% below this industry median. Based on the distribution chart, MeiraGTx Holdings ranks #896 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MeiraGTx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Equity-to-Asset compare to JBIO and VOR?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #896 out of 1414 companies for Equity-to-Asset. This places MeiraGTx Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. MeiraGTx Holdings' value of 0.54 is 20.6% below this benchmark. While the company's 10-year median is 0.53 vs. the industry median of 0.68, MeiraGTx Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeiraGTx Holdings's current Equity-to-Asset of 0.54 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current Equity-to-Asset is 0.54, which is near median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €70.41, compared to a current price of €11.40 — trading 83.8% below its estimated fair value. The current Equity-to-Asset is 0.54, which is near median its 10-year median of 0.53 and 20.6% below the Biotechnology industry median of 0.68. MeiraGTx Holdings' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Equity-to-Asset is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €11.40 is trading 83.8% below its estimated GF Value™ of €70.41.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
Equity-to-Asset: 0.54 (near median its 10-year median of 0.53)
GF Value™: €70.41 vs. price of €11.40 (83.8% below fair value)
Industry Position: 20.6% below the Biotechnology median (#896 of 1414)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
60GF Score
Get the complete analysis for FRA:328
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
